Researchers at the University of Oxford have developed an artificial intelligence scoring system, designated as HyperScore, capable of detecting hidden organ damage caused by hypertension before major cardiovascular events occur. Published in the journal Circulation, the study leverages machine learning to transcend traditional blood pressure metrics, providing a granular assessment of how elevated pressure affects individuals across multiple physiological systems. The research team analyzed clinical and imaging data from more than 27,000 UK Biobank participants, with external validation performed on 5,500 individuals from the US-based Atherosclerosis Risk in Communities study. By integrating hundreds of multi-organ parameters spanning the heart, brain, kidneys, vasculature, lungs, liver, and metabolic functions, the AI model identified six distinct clinical patterns termed HyperTrajectories. These trajectories map patient vulnerability to specific organ systems, revealing that hypertension manifests differently even when blood pressure readings appear comparable. Results indicate that patients with elevated HyperScore values face a significantly higher probability of future cardiovascular complications, including stroke and heart failure, regardless of standard blood pressure classifications. Among the evaluated indicators, brain changes captured via MRI scans emerged as the strongest predictors of hypertension-related injury. Senior author Professor Paul Leeson noted that computational approaches can uncover subclinical damage patterns that conventional metrics routinely miss. Dr. Mohanad Alkhodari, the study’s first author, emphasized that the findings advocate for a transition from blanket blood pressure management toward personalized treatment models that account for individual physiological vulnerabilities. Co-first author Dr. Winok Lapidaire highlighted that while current AI accuracy relies on extensive imaging, preliminary investigations suggest simpler clinical tools, such as routine electrocardiograms or standard health measurements, could eventually yield comparable risk stratification. Jill Jones of the Medical Research Council praised the initiative, noting its alignment with broader health technology objectives for earlier disease detection and targeted intervention. Despite the technological promise, researchers caution that HyperScore remains in a developmental phase and is not yet cleared for routine clinical deployment. Additional validation studies and real-world trials are required to integrate AI-driven organ damage scoring into standard medical workflows. The framework nonetheless marks a pivotal advancement in precision cardiology, positioning artificial intelligence as a critical bridge between systemic hypertension and individualized preventive care.